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Dichlorphenamide efficacy in the primary periodic paralyses  
Abstract  
Introduction: The periodic paralyses are rare genetic neuromuscular disorders that cause 
significant morbidity with episodic symptoms of muscle paralysis lasting from hours to 
weeks. There are no consensus treatment guidelines. Current treatment options include 
diuretics and the carbonic anhydrase inhibitor acetazolamide, but only anecdotal evidence 
and case reports support their use. 
Areas covered: We consider the evidence for the carbonic anhydrase inhibitor 
dichlorphenamide. This is the only treatment for periodic paralysis to have undergone 
randomised controlled trials. Although there has never been a comparative trial of 
dichlorphenamide and acetazolamide, many patients anecdotally report greater benefit from 
dichlorphenamide. However, it has been unavailable worldwide since 2011 until its recent re-
introduction to the market in late 2015. 
Expert opinion: There is level I evidence for the efficacy of dichlorphenamide in periodic 
paralysis. The ubiquitous nature of carbonic anhydrase enzymes mean that systemic 
administration of a carbonic anhydrase inhibitor leads to common dose-dependent side 
effects. In hypokalaemic periodic paralysis the benefits seem to outweigh these with 
acceptable tolerability. A successful consequence of recent randomised controlled trials was 
the re-introduction of dichlorphenamide to the commercial market following FDA approval 
in August 2015. Orphan status of dichlorphenamide for the treatment of periodic paralysis is 
to be welcomed but the current pricing is potentially prohibitive. 
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1. Introduction  
The primary periodic paralyses are rare genetic neuromuscular disorders. They include 
hypokalaemic periodic paralysis (hypoPP), hyperkalaemic periodic paralysis (hyperPP) and 
Andersen-Tawil Syndrome (ATS). HypoPP and hyperPP are disorders that only affect 
skeletal muscle1. ATS is characterised by a triad of periodic muscle paralysis, dysmorphic 
features and cardiac conduction abnormalities2, 3. 
Paroxysmal attacks of skeletal muscle weakness or paralysis accompanied by high or low 
levels of serum potassium are the defining clinical feature of the periodic paralyses. They 
usually present in the first or second decade and attacks of muscle weakness typically follow 
a period of immobility, especially after exercise. Other provoking factors are more specific to 
the sub-type of paralysis e.g. attacks in hypoPP are precipitated by large carbohydrate meals 
which stimulate insulin release and ultimately hypokalaemia1. Limb and trunk muscles are 
commonly affected, although any skeletal muscle including for example respiratory muscles 
may be involved4. Attacks of muscle weakness last typically from minutes to days (although 
can be weeks) depending on the sub-type and are extremely debilitating. The altered levels of 
serum potassium that accompany the attacks can induce cardiac arrhythmia5. In ATS cardiac 
conduction abnormalities and potentially fatal ventricular arrhythmias can occur 
independently of the muscle symptoms6, 7. 
The attacks of muscle paralysis are due to dysfunction of voltage gated ion channels which 
reside in the membrane of skeletal muscles8. These channels regulate muscle membrane 
excitability and control muscle contraction and relaxation. Genetic mutation of the genes 
coding for these ion channels intermittently causes prolonged depolarisation of the muscle 
membrane rendering the muscle inexcitable and unable to contract8. In hypoPP this is 
produced by an aberrant inward cation current that is created by arginine mutations of the 
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sarcolemmal sodium or calcium channel voltage sensors9. In hyperPP there is persistent 
sodium current due to impaired sodium channel inactivation and in ATS there is reduced 
potassium conductance. All three mechanisms are unified by destabilising the muscle 
membrane and leading to prolonged depolarisation.10  
The periodic paralyses are rare, the estimated point prevalence in England is: hyperkalemic 
periodic paralysis 0.17/100,000, hypokalemic periodic paralysis 0.13/100,000, and Andersen-
Tawil syndrome (ATS) 0.08/100,00011. 
Obtaining evidence of treatment efficacy in this group of disorders has partly been hampered 
by their rarity, as this impedes large adequately powered clinical trials. There are no 
recognised consensus treatment guidelines12.  
2. Overview of the market  
2.1 What are the unmet needs of currently available therapies?  
Treatment options include potassium sparing or wasting diuretics to maintain a normal serum 
potassium level as prophylactic treatment. In the case of hypoPP potassium supplements at 
the onset of an attack can be used to abort or reduce symptom duration and severity. However 
all of these options rely on case report or small series reporting of efficacy12. The majority of 
published data relates to the use of carbonic anhydrase inhibitors, acetazolamide and 
dichlorphenamide that have been used as prophylactic agents in all the periodic paralyses13-15 
although their exact mode of action is incompletely understood16. In 2002 Merck ceased 
production of dichlorphenamide and it has been unavailable worldwide since 2011. 
Acetazolamide remains widely available and affordable although is not licensed specifically 
for the treatment of periodic paralysis. There is no randomised controlled trial evidence 
supporting its use. However while it clearly has benefit across the periodic paralyses one 
retrospective series suggested up to 40-50% of patients with hypoPP are unresponsive to 
acetazolamide17. It is also our clinical experience from the UK National referral centre for 
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skeletal muscle channelopathies that a significant proportion of patients with PP respond 
significantly better to dichlorphenamide than acetazolamide. 
2.2 Which competitor compounds/classes of compounds are in the clinic/late 
development?  
Activation of a cotransporter of sodium–potassium–and two chloride ions (NKCC) promotes 
chloride accumulation within muscle cells. Intramuscular accumulation of chloride 
contributes to the propensity of the muscle membrane to become depolarised (and muscle 
paralysis to occur) in a low potassium environment18. Bumetanide is a diuretic that inhibits 
this cotransporter. Based on the hypothesis that inhibiting intramuscular chloride 
accumulation would reduce or prevent muscle membrane depolarisation and muscle paralysis 
in hypoPP two studies examined the in vitro and in vivo effects of bumetanide using a murine 
model19, 20. In both scenarios bumetanide was effective in aborting an episode of muscle 
weakness in the presence of hypokalaemia and in preventing muscle weakness from 
occurring if given prior to the induction of hypokalaemia. In the in vivo murine model its 
benefit in recovering or sustaining muscle strength was similar to acetazolamide in individual 
cases, although a greater number of animals in total responded to bumetanide than 
acetazolamide20. 
As a diuretic, bumetanide can also produce hypokalaemia. Whether this would be clinically 
relevant in hypoPP is unknown.  A clinical safety study is currently open using intravenous 
bumetanide versus placebo in hypoPP. The half-life of bumetanide however is very short, 
approximately one and a half hours which will inhibit its use as a daily prophylactic. It may 
however have potential to be used as a prophylactic agent if taken just prior to activities 
known to provoke an attack of paralysis e.g. before sport. 
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3. Introduction to dichlorphenamide  
The carbonic anhydrase inhibitor acetazolamide was initially given to patients with 
hyperkalaemic periodic paralysis in which attacks of paralysis occur in conjunction with 
raised serum potassium levels because of its ability to increase urinary potassium excretion 13. 
Despite seeming to be an unlikely candidate for treatment of hypokalaemic periodic 
paralysis, a prophylactic benefit was subsequently also reported in this disorder 21, 22.  
Experimental work has  supported a rationale for carbonic anhydrase inhibitors due to their 
effect on pH 23, improved sarcolemmal conductance of potassium via calcium activated 
potassium channels24, 25 and observation of a reduced number of vacuoles seen in the muscle 
biopsies of potassium depleted rats administered acetazolamide26. Acetazolamide and 
dichlorphenamide have been the mainstay of treatment for the periodic paralyses for the last 
half a century. 
4. Chemistry  
Carbonic anhydrases are ubiquitously expressed isoenzymes that catalyse the reversible 
conversion of water and carbon dioxide to protons and bicarbonate with corresponding 
effects on pH balance. This reaction is key to numerous physiological processes including 
respiration, pH and CO2 homeostasis; electrolyte secretion, biosynthetic reactions e.g. 
gluconeogenesis, lipogenesis and ureagenesis, bone resorption and calcification27. 
Dichlorphenamide (DCP), a benzenedisulfonamide, is a carbonic anhydrase inhibitor (CAI)28.  
5. Pharmacodynamics, pharmacokinetics and metabolism 
Carbonic anhydrase inhibitors have a weak diuretic action29. They act on the proximal tubule 
of the kidney to inhibit bicarbonate resorption. Consequently there is increased bicarbonate, 
sodium and potassium excretion in the urine which causes an accompanying diuresis and 
metabolic acidosis. Although they have been used in the management of hypertension and 
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congestive cardiac failure, other more potent diuretics have largely superseded their use other 
than as additive agents. 
One of their main therapeutic roles has been in the treatment of glaucoma30. The major 
constituent of aqueous humour is sodium bicarbonate. Carbonic anhydrase inhibitors reduce 
the excretion of this with a resultant drop in intra-ocular pressure.  
The ability of CAIs to inhibit carbonic anhydrases have since been manipulated for numerous 
other medical conditions including epilepsy, high altitude sickness, raised intracranial 
pressure, episodic ataxia, myotonic disorders31 and periodic paralysis. More recent research 
has suggested they could be developed in newer fields including osteoporosis, obesity and 
oncology27. 
Systemic CAIs are well absorbed via the GI tract and excreted unchanged by the kidneys. 
Dose adjustments may therefore need to be made for impaired creatinine clearance. A single 
oral dose has benefit for approximately 8 to 12 hours. Carbonic anyhdrases are ubiquitously 
expressed32, and systemic administration of a CAI leads to unselected CA enzyme blockade. 
There are multiple isoforms of carbonic anhydrase and each carbonic anhydrase inhibitor has 
a variable affinity for each isoform28.  
Sulphonamides include drugs with both antibacterial and non-antibacterial properties, DCP 
and acetazolamide belonging to the latter group. Allergic reactions to sulphonamide 
antibiotics are relatively common and there is often concern over cross-reactivity when using 
CAIs33. However the antibiotic sulphonamides contain an arylamine group (an amine 
attached to a benzene ring- see figure 1) which is thought to be implicated in the majority of 
allergic reactions. DCP and other CAIs lack this moiety and they have been used safely in 
those with known sulphonamide antibiotic sensitivity but caution is still advised especially in 
cases of severe allergy34. 
7 
 
 
6. Clinical efficacy  
The initial drug safety profile of DCP was ascertained from studies in its primary indication, 
the treatment of glaucoma. Dose efficacy and ascertainment of any disease specific side 
effects in periodic paralysis were indicated from non-randomised and often small scale 
studies although more recent phase III studies have now added to this body of knowledge. 
 
6.1 Phase III trials 
In 2000 a randomised double blind placebo controlled trial was reported which attempted to 
address the question of DCP efficacy and tolerability when used in the treatment of periodic 
paralysis35. In a seven site study, DCP was compared to placebo in two groups of patients, 
those with a diagnosis of hypoPP and those classed as potassium sensitive periodic paralysis 
by the investigators. This latter group encompassed hyperkalaemic periodic paralysis and 
paramyotonia congenita with episodes of muscle paralysis. Diagnosis was largely based on 
clinical criteria and a genetic mutation was not essential for inclusion. Trial design consisted 
of an eight week baseline assessment of attack frequency and severity followed by two cross 
over nine week treatment phases (DCP or placebo)  separated by a  nine week washout phase. 
Forty two patients with hypoPP were enrolled. Thirty four completed the study. Two 
dropouts were due to inability to tolerate adverse events of DCP (dizziness and difficulty 
concentrating at work) and the others lost to follow up or requested withdrawal for other 
reasons. Based on those who completed the trial the primary end point of intolerable increase 
in attack frequency or severity was reached in fifteen, two reaching the end point in both 
treatment arms (DCP and placebo) and thirteen exhibiting a preference. For those exhibiting a 
preference eleven were taking placebo and two taking DCP. Secondary endpoints of 
frequency and severity of attacks were also significantly lower in the DCP treated group.  
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Thirty one patients with PSPP were enrolled, twenty four completing both treatment arms of 
the study. Two of the dropouts were due to adverse events whilst taking DCP (rash and 
memory loss). Of those who completed the study a significantly greater reduction in attack 
frequency (the primary outcome for this group) and severity was demonstrated with DCP 
compared to placebo. 
This trial was the first to provide randomised placebo controlled evidence for the use of DCP 
in the periodic paralyses and supported clinical impression of efficacy.  
A second randomised placebo controlled trial with a one year open label extension phase 
attempting to ascertain if benefit was maintained in the longer-term was reported in 201636. 
This twelve centre international study randomised participants with a diagnosis of hypoPP or 
hyperPP between 2007 and 2013. Diagnosis again encompassed a clinically based criteria 
and genetic diagnosis was not essential but 75% of hypoPP and 67% of hyperPP participants 
did have a genetic diagnosis made. Participants were randomised to an initial 9 week blinded 
treatment phase with either DCP or placebo followed by one year of continued treatment with 
DCP. The original trial design had included randomisation to either DCP or acetazolamide. 
However, this subsequently had to be dropped, as a significant proportion of patients report 
DCP to be more effective than acetazolamide and were reluctant to participate when there 
was a chance of being randomised to acetazolamide. Forty four hypoPP and twenty one 
hyperPP participants were randomised to the double blind phase. Five hypoPP participants 
receiving placebo, but none receiving DCP were moved prematurely before the end of the 
blinded nine week treatment phase to the open label DCP phase due to acute worsening of 
symptoms. This was mirrored in the hyperPP arm, with two receiving placebo, but none 
receiving DCP moving early into the open label phase.  
In the hypoPP group there were statistically significant improvements in attack rate, severity 
and duration with DCP during the double-blind nine week treatment phase. There were also 
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improvements in quality of life demonstrated by the physical component score of the SF-36. 
Improvement in attack frequency also seemed to persist during the extension phase. In the 
hyperPP group there was a significant improvement in attack severity but not rate of attacks 
or attack duration. No changes were seen in quality of life. Despite an admirable attempt by 
the authors to recruit subjects with a very rare disease into this trial they did not ultimately 
meet their recruitment targets particularly for hyperPP and this may have affected the 
outcomes. 
 
6.2 Post-marketing surveillance  
Following the conclusion of this international study DCP was granted Food and Drug 
Administration approval in August 2015. Taro pharmaceuticals began commercial 
manufacture in the USA but uptake in clinical practice has been slow due to expense and 
there are no post-marketing surveillance studies currently available.  
 
7. Safety and tolerability  
Carbonic anhydrase inhibitors can interact with other common medications e.g. non-steroidal 
anti-inflammatory drugs and anti-epileptics to potentially cause a severe metabolic acidosis 
or enhance drug toxicity. There is also a risk of severe acidosis in those with renal, liver or 
respiratory disease. A careful medical and drug history is therefore required before initiating 
these medications37. 
Common dose dependent adverse effects of DCP include numbness and tingling of the 
extremities, metallic taste, fatigue, loss of libido, anorexia, headache, transient myopia and 
renal calculi. Short-term use in humans indicates that these adverse effects are minimal for 
single doses of less than 200 mg38. In glaucoma studies DCP was less well tolerated than 
ACZ which likely reflects its greater potency as a CAI39. In general in ophthalmic medicine 
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the side effects of systemic CAIs were rather intolerable and topical preparations developed. 
However the dosage of DCP used in glaucoma, 50 mg every 6 hours, was twice the average 
dosage used in studies demonstrating the efficacy of DCP for the treatment of PP35, 36. In the 
2016 study of DCP in periodic paralysis 18% of participants taking DCP withdrew due to 
adverse events, the majority in the long-term extension phase36. Although paraesthesia was 
the most common side effect occurring in 47% of those taking DCP it was never the cause of 
withdrawal. Cognitive disorder was the second most commonly noted adverse event (19%) 
and prominent enough that the authors recommended all patients being offered DCP should 
be counselled about the possibility, especially those in mentally demanding occupations. The 
development of renal calculi is often a concern when using long-term CAIs. Of the 53 
participants (39 hypoPP, 14 hyperPP) who underwent renal tract assessment at the end of the 
trial eight developed new renal calculi (7 hypoPP, 1hyperPP) and two hypoPP participants 
had an increase in size of pre-existing calculi36. One participant withdrew because of painful 
calculi but it is unclear if the others were symptomatic or if treatment was necessary. 
However this indicates that monitoring of the renal tract for calculi in those on long-term 
DCP will be essential. 
 
 
8. Regulatory affairs  
Dichlorphenamide was originally marketed by Merck & CO., INC., 1985 NDC #51672-4144 
for the treatment of glaucoma but Merck ceased manufacture in 2002. We are not aware of 
any adverse regulatory actions that have been taken against Dichlorphenamide in any country 
and the FDA DOCID: fr06au07-57 asserts that it was not withdrawn from sale for reasons of 
‘safety or effectiveness’. Following the success of the international trials of DCP, it was 
granted orphan drug status for periodic paralysis by the FDA in the USA and commercial 
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manufacture began by Taro pharmaceuticals. The price was approximately $100 000 per 
patient per year. Uptake was very low and in May 2016 Taro announced it was stopping 
commercial production in the USA. An application for a European marketing authorisation is 
currently being considered although the final price in Europe is yet to be established.  
 
9. Conclusion  
There is level I evidence for the efficacy of dichlorphenamide in the treatment of hypoPP and 
hyperPP. There have been no randomised controlled trials in Andersen-Tawil syndrome but 
case reports support benefit and the clinical symptom of periodic paralysis mirrors the other 
two conditions. Although there have been no head to head studies with acetazolamide, many 
patients report a much better response to DCP in clinic. It is unknown if side effects are also 
comparatively more troublesome although the incidence was relatively high in one 
randomised controlled trial. However benefit did seem to outweigh adverse events in the 
hypoPP arm of that study.  
 
10. Expert opinion 
The randomised trial evidence supports the clinical impression gained over many years; DCP 
is an effective treatment for periodic paralysis. Adverse events are relatively common but for 
the majority tolerable. Currently, a significant proportion of patients with periodic paralysis 
do not have adequate control of their symptoms from available treatments and suffer 
unnecessary morbidity as DCP is not available to them. The cost of dichlorphenamide when 
marketed as a treatment for glaucoma was approximately £100 for 100 tablets. It was a huge 
success for the rare disease community to be able to conduct randomised controlled trials in 
such rare disease. Orphan status of dichlorphenamide for the treatment of periodic paralysis 
was celebrated but the ensuing price rise of DCP to $100 000 per patient per year when 
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brought back to the commercial market has caused significant affordability issues for 
healthcare providers.  Hopefully if EMA approval is obtained and DCP launched in Europe it 
will be affordable to the health service. 
 
 
 
Drug Summary Box 
Drug name: dichlorphenamide   
Phase: commercially manufactured USA August 2015 (ceased May 2016). Application for 
EMA pending. 
Indication: Hypokalaemic periodic paralysis, Hyperkalaemic periodic paralysis and 
Andersen-Tawil Syndrome 
Pharmacology description/mechanism of action: Carbonic anhydrase inhibitor 
Route of administration: Oral 
Pivotal trial(s):  
Tawil R, McDermott MP, Brown R, Jr., et al. Randomized trials of dichlorphenamide in the 
periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol 2000;47:46-53 
Sansone VA, Burge J, McDermott MP, et al. Randomized, placebo-controlled trials of 
dichlorphenamide in periodic paralysis. Neurology 2016;86:1408-16 
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